



EFW

PATENT  
Attorney Docket No.: LLOYD1100

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Yong, et al. Art Unit: 1654  
Serial No.: 10/727,020 Examiner: Not Yet Assigned  
Filed: December 2, 2003  
Title: COMPOSITIONS AND METHOD FOR TREATMENT OF  
STEROID/NUCLEAR RECEPTOR-MEDIATED DISEASES

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL SHEET**

Sir:

Transmitted herewith are the following documents for the above-identified patent application:

1. Information Disclosure Statement (2 pages);
2. PTO-1449 Form (2 pages);
3. Seventeen (17) References; and
4. Return Receipt Postcard.

**CERTIFICATION UNDER 37 CFR §1.8**

I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, February 9, 2005 in an envelope addressed to: Mail Stop Amendment: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Stephanie Sharrett

Name of Person Mailing Paper

Signature *Stephanie Sharrett* February 9, 2005


In re Application of:  
Yong, et al.  
Application No.: 10/727,020  
Filed: December 2, 2003  
Page 2

PATENT  
Atty. Docket No.: LLOYD1100

No other fees are deemed necessary in connection with the filing of this paper. However, the Commissioner is hereby authorized to charge any other fees that may be associated with this communication, or credit any overpayment to Deposit Account No. 07-1896. A duplicate copy of this sheet is enclosed.


Respectfully submitted,

Date: February 9, 2005



Lisa A. Haile, J.D., Ph.D.  
Reg. No.: 38,347  
Telephone: (858) 677-1456  
Facsimile: (858) 677-1465

DLA PIPER RUDNICK GRAY CARY US LLP  
4365 Executive Drive, Suite 1100  
San Diego, California 92121-2133  
**USPTO Customer Number 28213**



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number 10/727,020

Filing Date 2 December 2003

First Named Inventor YONG, Eu Leong

Art Unit 1654

Examiner Name Unassigned

Attorney Docket Number LLOYD1100

Sheet

1

of

2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A	ATKINSON et al. "Red clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial" Breast Cancer Research, Vol 6 No. 3, 2003	
	B	LINSEISEN et al. "Dietary phytoestrogen intake and premenopausal breast cancer risk in a German case-control study" Int. J. Cancer 110, 284-290, 2004	
	C	JARRED et al. "Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones" Vol 11, 1689-1696, 2002	
	D	Pharmacopoeia of the People's Republic of China, "Radix astragali" Chemical Industry Press, Beijing, China, Vol. 1, 142, 1997	
	E	QIAN et al. "Viral etiology of chronic cervicitis and its therapeutic response to a recombinant interferon" Chinese Medical Journal, 103(8): 647-651, 1990	
	F	SUN A. and CHIANG C.P "Levamisole and/or Chinese medicinal herbs can modulate the serum level of squamous cell carcinoma associated antigen in patients with erosive oral lichen planus" J Oral Pathol Med 30: 542-8, 2001	
	G	LU et al. "Preventive effect of radix astragali on insulin resistance caused by tumor necrosis factor-alpha, Zhongguo Zhong Xi Yi Jie He Za Zhi, 19(7): 420-2, 1999 (text in Chinese)	
	H	MA et al. "Mechanisms of the therapeutic effect of astragalus membranaceus on sodium and water retention in experimental heart failure" Chinese Medical Journal, 111(1): 17-23, 1998	
	I	YANG et al. "Treatment of experimental coxsackie B-3 viral myocarditis with astragalus membranaceus in mice" Chinese Medical Journal, 103(1): 14-18, 1990	
	J	MA et al. "Preparative isolation and purification of two isoflavones from astragalus membranaceus Bge. var. mongholicus (Bge) Hsiao by high-speed counter-current chromatograph" Journal of Chromatograph A, 992: 193-197, 2003	

Examiner  
Signature

Date


Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Substitution for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/727,020
Filing Date	2 December 2003
First Named Inventor	YONG, Eu Leong
Art Unit	1654
Examiner Name	Unassigned
Attorney Docket Number	LLOYD1100

Sheet 2 of 2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	K	KAJIMURA et al. "Polysaccharide of astragali radix enhances IgM antibody production in aged mice" Biol. Pharm Bull, Vol 20, No. 11: 1178-1182, 1997	
	L	ZHANG et al. "Regulation of the fibrinolytic potential of cultured human umbilical vein endothelial cells: astragaloside IV downregulates plasminogen activator inhibitor-1 and upregulates tissue-type plasminogen activator expression" J Vasc Res, 34: 273-280, 1997	
	M	SHIRATAKI et al. "Antioxidative components isolated from the roots of astragalus membranaceus bunge (astragali radix)" Phytotherapy Research, Vol. 11, 603-605, 1997	
	N	Shizuo TODA and Yoshiaki SHIRATAKI "Inhibitory effects of isoflavones in roots of astragalus membranaceus bunge (astragali radix) on lipid peroxidation by reactive oxygen species" Phytotherapy Research, Vol 12, 59-61, 1998	
	O	EISOHLY et al. "Antigiardial isoflavones from machaerium aristulatum" Planta Medica 65, 490, 1999	
	P	KRAFT et al. "Antiplasmodial activity of isoflavones from andira inermis" Journal of Ethnopharmacology, 73: 131-135, 2000	
	Q	Richard J. MIKSICEK "Interaction of naturally occurring nonsteroidal estrogens with expressed recombinant human estrogen receptor" J. Steroid Biochem. Molec. Biol., Vol 49 No. 2/3, 153-160, 1994	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.